EAC-MRH: Harmonizing Clinical Trial Approvals in East Africa

Regulatory Harmonization Impact on Cross-Border Clinical Trial Approvals in EAC

This article examines the impact of regulatory harmonization on the approval process for clinical trials in the East African Community, enhancing drug accessibility.

Dr. Elena Rossi PhD Pharmaceutical Sciences · EMA Regulatory Affairs Editor

Reviewed by Dr. Anil Kapoor Medical Oncologist, Medical Reviewer

Wednesday, April 29, 2026 11 min read Updated Jul 13, 2026

Quick Answer

This article examines the impact of regulatory harmonization on the approval process for clinical trials in the East African Community, enhancing drug accessibility.

Key Questions

What is the EAC-MRH initiative?
How does EAC-MRH differ from the old fragmented system?
Is EAC-MRH fully operational for clinical trials?
What countries are part of EAC-MRH?
How does EAC-MRH connect to the African Medicines Agency?

The East African Community Medicines Regulatory Harmonization (EAC-MRH) initiative streamlines cross-border clinical trial approvals across 7 partner states through joint scientific assessments and standardized applications. This framework reduces regulatory duplication while preserving national authority over final decisions, accelerating patient access to investigational therapies in East Africa.

Key Takeaways

Regional scope: The EAC-MRH includes 7 partner states—Burundi, Kenya, Rwanda, South Sudan, Tanzania, Uganda, and Zanzibar—each with a National Medicines Regulatory Authority participating in joint assessments (EAC).
Implementation status: While medicines registration harmonization is operational, clinical trial approval procedures remain an expansion area under ongoing development and capacity building.
Mechanism: Standardized Clinical Trial Applications (CTAs), joint scientific reviews, and coordinated ethics committees reduce approval timelines compared to the previous fragmented approach.
Continental link: The African Medicines Agency (AMA) Treaty entered into force on November 5, 2021, with 17 member states having ratified and 26 having signed as of that date.
GCP alignment: The ICH E6(R3) Good Clinical Practice guideline was adopted on January 6, 2025, providing updated standards for trial conduct across harmonized regions.

What Is the EAC-MRH Initiative?

The EAC-MRH initiative operates under the East African Community to coordinate pharmaceutical regulatory processes across partner states. According to the EAC, the programme has developed guidelines for medicines registration, GMP inspections, pharmacovigilance, post-marketing surveillance, medical devices, and clinical trial control.

Each partner state maintains its own National Medicines Regulatory Authority (NMRA). These include ABREMA in Burundi, the Pharmacy and Poisons Board (PPB) in Kenya, Rwanda FDA, South Sudan's Drug and Food Control Authority (DFCA), Tanzania's TMDA, Uganda's NDA, and Zanzibar's ZFDA. While these authorities retain final approval authority, they collaborate on joint scientific assessments.

The initiative addresses longstanding inefficiencies in multi-country clinical trials. Previously, sponsors navigated independent approval processes in each country, submitting separate applications with varying formats and requirements. This fragmentation created administrative burden and inconsistent timelines.

How Does the Harmonized Approval Process Work?

The EAC-MRH framework introduces three coordinated mechanisms for clinical trial approvals:

Standardized Clinical Trial Applications. The initiative has standardized CTA formats across member countries. Rather than preparing country-specific applications with varying documentation, sponsors submit harmonized applications meeting requirements across multiple jurisdictions. This standardization reduces application deficiencies caused by format inconsistencies.

Joint Scientific Assessments. National regulatory authorities collaborate to evaluate trial protocols, investigator qualifications, and safety monitoring plans. WHO's AVAREF programme provides assessment tools including Clinical Evaluation Grids, Statistical Evaluation Grids, Non-Clinical Evaluation Grids, and Quality Evaluation Grids that support standardized technical reviews.

Coordinated Ethics Reviews. Research Ethics Committees (RECs) participate in joint or mutually recognized ethical assessments. While individual countries retain authority over final ethics approval, the harmonized approach reduces delays from sequential reviews and improves consistency in informed consent standards.

What Progress Has Been Made?

The EAC-MRH initiative originally focused on medicines registration before expanding to clinical trials. EAC guidelines cover procedural aspects for marketing authorization applications, including new applications, renewals, and variations.

Clinical trial harmonization presents particular complexity compared to medicines registration. It requires alignment of technical requirements, ethics review standards, informed consent procedures, and safety monitoring protocols. The EAC-MRH has prioritized these elements in its expansion roadmap.

Implementation varies by partner state. Some countries have adopted harmonized procedures while others continue parallel independent processes. Capacity building remains essential, as some national regulatory authorities require enhanced technical expertise and infrastructure to participate effectively in joint assessments.

How Does EAC-MRH Connect to Broader African Initiatives?

The EAC-MRH operates within a broader context of African regulatory harmonization. The African Medicines Agency (AMA) Treaty entered into force on November 5, 2021, thirty days after Cameroon deposited the 15th instrument of ratification. As of November 2021, 17 member states had ratified the treaty and 26 had signed.

The AMA represents a continental harmonization effort encompassing the entire African Union. The EAC-MRH occupies a middle position—more developed than many sub-regional initiatives but operating within a more limited geographic scope than the AMA. This allows for targeted implementation suited to East African regulatory contexts.

WHO supports these efforts through the African Vaccine Regulatory Forum (AVAREF) and related initiatives. AVAREF documents provide standardized frameworks for clinical trial submission, evaluation, and oversight across African regulatory authorities. These include CTA checklists, assessment tools, and GCP inspection guidelines.

What Standards Guide Clinical Trials in the Region?

Clinical trials in EAC member states follow international Good Clinical Practice standards. The ICH E6(R3) guideline for Good Clinical Practice was adopted on January 6, 2025. This update to the international standard for clinical trial conduct provides modernized approaches to quality management and risk proportionality.

The ICH E6(R3) guideline builds upon previous versions adopted in 1996 (E6) and 2016 (E6 R2). Regulatory members of the ICH Assembly endorsed the latest revision under Step 4 of the ICH process, making it recommended for adoption by regulatory bodies in ICH regions including through harmonized African frameworks.

What Are the Implications for Pharmaceutical Sponsors?

Regulatory harmonization in the EAC region reduces complexity for multi-country clinical trials. Sponsors can expect streamlined approval processes and reduced administrative burden compared to navigating independent country-by-country approvals. However, the ongoing nature of implementation means sponsors should verify current harmonization status in specific partner states.

Streamlined cross-border approval processes enhance the region's attractiveness for clinical research investments. Pharmaceutical companies and contract research organizations can conduct multi-country trials with reduced regulatory complexity, potentially lowering trial costs and timelines. This efficiency may encourage sponsors to include East African sites in global clinical trial networks.

Healthcare systems benefit from participation in global clinical research networks and access to evidence generated through coordinated trials. Patients may gain earlier access to investigational therapies through more efficient trial enrollment across multiple East African sites.

Frequently Asked Questions

What is the EAC-MRH initiative?

The East African Community Medicines Regulatory Harmonization (EAC-MRH) initiative coordinates regulatory processes for clinical trial approvals across 7 partner states in East Africa. Established under the East African Community, it introduces joint scientific assessments, standardized Clinical Trial Applications, and coordinated ethics reviews to reduce duplicative regulatory processes while maintaining each country's authority over final approval decisions.

How does EAC-MRH differ from the old fragmented system?

Previously, sponsors submitted separate applications to each national regulatory authority with different formats and requirements. The EAC-MRH framework enables standardized applications, joint scientific reviews, and coordinated ethics assessments, allowing sponsors to conduct trials simultaneously across multiple countries based on harmonized regulatory decisions rather than sequential country-by-country approvals.

Is EAC-MRH fully operational for clinical trials?

No. While the EAC-MRH framework has made substantial progress for medicines registration, full implementation for clinical trial approvals remains under development. The initiative originally focused on marketing authorization, and clinical trial harmonization continues to expand across partner states with ongoing capacity building and infrastructure development.

What countries are part of EAC-MRH?

The EAC-MRH initiative includes 7 partner states: Burundi, Kenya, Rwanda, South Sudan, Tanzania, Uganda, and Zanzibar. Each maintains a National Medicines Regulatory Authority that participates in joint assessments while retaining final approval authority within its jurisdiction.

How does EAC-MRH connect to the African Medicines Agency?

The EAC-MRH operates as a sub-regional initiative that supports the broader African Medicines Agency (AMA). The AMA Treaty entered into force on November 5, 2021, following ratification by 15 African Union member states. EAC-MRH experiences inform continental harmonization efforts while AMA guidelines provide templates adaptable to regional contexts.

Primary Sources

East African Community. "EAC Medicines Regulatory Harmonization (EAC-MRH) Programme." Official programme documentation with contacts for all 7 partner state regulatory authorities.
African Union. "Treaty for the establishment of the African Medicines Agency (AMA) enters into force." Press release, November 9, 2021. Treaty entered into force November 5, 2021; 17 ratifications, 26 signatories.
World Health Organization. "AVAREF Documents and Tools." Standardized frameworks for clinical trial evaluation and oversight across African regulatory authorities.
International Council for Harmonisation. "Guideline for Good Clinical Practice E6(R3)." Adopted January 6, 2025. Step 4 final guideline for clinical trial conduct.
East African Community. "EAC Guidelines on Procedural Aspects for Applications for Marketing Authorization of Pharmaceutical Products." Part X guidelines covering new applications, renewals, and variations.